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One-pot synthesis, characterisation and kinetic
stability of novel side-bridged pentaazamacrocyclic
copper(II) complexes
Helen M. Betts,* Soﬁa I. Pascu,* Antoine Buchard,
Paul D. Bonnitcha and Jonathan R. Dilworth*
This work focuses on a new, one-step facile, synthesis
method for a new family of side-bridged copper(II)
complexes based on 15-membered pentaazamacrocycles
and their detailed spectroscopic and structural
characterisation. Syncrotron X-ray crystal structure backed
up by DFT computational modeling and further
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5One-pot synthesis, characterisation and kinetic
stability of novel side-bridged
pentaazamacrocyclic copper(II) complexes†
Helen M. Betts,‡*a Soﬁa I. Pascu,*b Antoine Buchard,b Paul D. Bonnitchaa
and Jonathan R. Dilworth*a10
15
20Single-step synthetic protocols are reported for novel macrocyclic
copper(II) complexes incorporating a piperazine unit in the ligand
backbone. Synchrotron X-ray structure determination conﬁrmed the
copper(II) coordination geometry in the solid state as distorted square
pyramidal with chloride occupying the axial position above the N4
ligand plane. DFT calculations, electrochemical and UV/vis investiga-
tions in biological media all conﬁrmed that compounds in this class
have high stability, and compare well in both thermodynamic and
kinetic terms with the ubiquitous Cu(II) cyclam compounds, and are
therefore of relevance for future use as synthetic scaﬀolds for the
binding, transport and tracing of copper ions in vitro.25
30
35
40Introduction
Radiopharmaceuticals are compounds that are labelled with a
radioactive isotope, and designed to accumulate specically in a
target tissue in vivo. Once localised in their target tissue, emis-
sions from decay of the radioisotope allow non-invasive molec-
ular imaging, or delivery of a therapeutic radiation dose. Copper
complexes are attractive candidates for development as radio-
pharmaceuticals for a number of reasons.1,2 Several copper
radioisotopes are available which decay by various modes, with
half-lives ranging from a few minutes to several days. The choice
of radioisotope, copper-60 (b+, EC, t1/2 ¼ 0.38 h), copper-62 (b+,
EC, t1/2¼ 0.16 h) copper-64 (b+, EC, b, t1/2¼ 12.7 h) or copper-67
(b, t1/2 ¼ 62 h), is determined based on the desired application
and isotope availability.3 The coordination chemistry of copper is
well studied, its chemistry limited to two main oxidation states,
and radiolabelling is typically achieved by simple heating of aaboratory, Manseld Road, Oxford, OX1
ath, BA2 7AY, UK. E-mail: s.pascu@bath.
(ESI) available. CCDC 975683. For ESI
other electronic format see DOI:
Hospitals NHS Trust, PET/CT Centre,
G5 1PB, UK
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45pro-ligand in a buﬀered aqueous solution of the radioisotope.
New ligands designed to deliver radiocopper specically to
diseased tissue are therefore of great interest for both imaging
and therapeutic applications. The most widely used approach for
development of copper radiopharmaceuticals is based on a
bifunctional chelate (BFC).4 A BFC contains a ligand set for
coordination of the copper ion and a biological targeting group,
joined by a covalent linker (Fig. 1).
Tetraaza macrocycles have been extensively explored as
ligands for copper radiopharmaceuticals.5 Copper(II) complexes
of cross-bridged cyclam derivatives based on 2 have signi-
cantly higher kinetic stability in vivo than complexes of cyclam,
1, and recent research eﬀort has been focussed on developing
bifunctional chelates of these complexes1,6,7 (Fig. 2). Side-
bridged analogues containing a piperazine unit in the macro-
cycle backbone, such as Et-cyclam 5, have also been reported.8
In acid dissociation studies, copper complexes [Cu5][ClO4]2 and
[Cu1][ClO4]2 are of similar stability, but the experimental
conditions used in these studies were not directly relevant to
those experienced by BFCs in vivo.9Despite the extensive reports
in the literature of bridged 14-membered copper(II) macrocycles
and their bifunctional chelates, their 15-membered analogues
have not been studied to such extent.
The 15-membered tetraaza macrocycle 6 and its copper(II)
complex are key examples of 15-membered macrocycles which
have a tethering group for conjugation to a biologically active
molecule.10 The considerable advantage of 6 over the more
popular 14-membered derivatives is that it can be prepared in
good yield in a simple, one-step procedure from commercially
available tetramines, formaldehyde and nitromethane. The aim
of our work was to develop this chemistry as a facile route toFig. 1 Schematic representation of a bifunctional chelator.
RSC Adv., 2014, xx, 1–7 | 1
50
Fig. 2 Chemical structures of ethylene strapped macrocyclic ligands.
Fig. 3 ORTEP representation (where displacement ellipsoids are
drawn at the 40% probability level) of the molecular structure of 7b
resulting from synchrotron X-ray diﬀraction measurements. The
perchlorate counter-ion has been omitted for clarity.
Scheme 1 Synthesis of macrocyclic complexes 7a and 7b.
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40prepare novel side-bridged macrocycles, and examine the suit-
ability of the resulting copper(II) complexes as potential radio-
pharmaceuticals. This article describes the synthesis,
characterisation and stability assessment of novel 15-membered
copper(II) macrocycles 7a and 7b (Fig. 2).Fig. 4 Cyclic voltammograms for compound 7a in 0.1 M NaCl at scan
rates 25, 150 and 300 mV s1.
45
50
55Results and discussion
Copper(II) macrocycle synthesis
The novel complexes 7a and 7b were prepared in a one-step
method using primary amines to complete the cyclisation
step.11 The side-bridged tetramine bis(3-aminopropyl)piperazine
was reacted with formaldehyde and either benzylamine or allyl-
amine in the presence of copper(II) nitrate (Scheme 1).
The deep blue reaction mixtures were heated at reux for
24 h, and then cooled to room temperature. It proved impos-
sible to isolate a pure perchlorate salt directly from the reaction
mixture, so the reaction solution was puried on a Sephadex-SP
C25 column, eluted with sodium chloride solution. Aer addi-
tion of aqueous sodium perchlorate to the major band eluted
from the column, solutions were stored at 4 C. Aer 14 days,
7-benzyl-1,5,7,9,13-penta-aza-(1,13-ethano)-cyclopentadecane2 | RSC Adv., 2014, xx, 1–7chlorocopper(II) perchlorate 7a and 7-allyl-1,5,7,9,13-penta-
aza-(1,13-ethano)-cyclopentadecane chloro copper(II) perchlorate
7b, were isolated as ne blue needles obtained in 68% and 59%
yield, respectively. Elemental analysis conrmed the purity of
both complexes. The UV/vis spectra of 7a and 7b showed two
main bands at 285 nm and 571 nm. The weak d–d transition
observed at 571 nm was shied relative to that reported in the
literature for [Cu1][ClO4]2 and [Cu5][ClO4]2, consistent with a
coordinated axial ligand for the new complexes.12,13
Crystals of 7b suitable for X-ray analysis were isolated by slow
diﬀusion of Et2O into a solution of the complex in MeCN. Data
was collected using radiation from a synchrotron source
(Daresbury, UK). Themolecular structure is shown in Fig. 4, and
selected bond lengths and angles are given in Table 1.
The copper(II) ion is coordinated in distorted square based
pyramidal geometry. The bonds between the copper ion and
piperazine nitrogen atoms (N3) and (N4) are slightly longer than
the copper to secondary amine bonds (N1) and (N2). The
ethylene bridging unit causes the piperazine fragment bite
angle to be 72.25, which is notably more acute of than the other
N–Cu–N angles as a result of the steric restriction. In the
previously reported crystal structures of [Cu4][ClO4]2 and [Cu5]
[ClO4]2, the analogous angles are 74.00 and 77.71 respectively,
illustrating the restraint imposed by the piperazine side-
bridge.9 In the structure of 7b, a chloride counter-ion is coor-
dinated to the copper ion in an axial site, with a long bond ofThis journal is © The Royal Society of Chemistry 2014
Table 1 Signiﬁcant molecular parameters for the X-ray structure of 7b
Bond Bond length A˚ Bond Angle 
Cu(1)–N(1) 2.048 N(1)–Cu(1)–N(2) 91.08
Cu(1)–N(2) 2.043 N(2)–Cu(1)–N(4) 95.45
Cu(1)–N(3) 2.091 N(4)–Cu(1)–N(3) 72.25
Cu(1)–N(4) 2.112 N(3)–Cu(1)–N(1) 94.62
Cu(1)–Cl(3) 2.462
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202.462 A˚. A non-coordinating perchlorate counter ion is also
present (not shown in the gure). In the crystal structure of [Cu5]
[ClO4]2, the copper ion is found in a distorted square planar
environment with deviation of 0.06 A˚ towards the perchlorate
counter-ion, from the plane dened by the nitrogen atoms.9 A
similar distortion of 0.11 A˚ was observed in the crystal structure of
non-cyclic structure [Cu4][ClO4]2.9 The distortion of the copper(II)
from the plane towards the chloride in 7b is more pronounced,
and is 0.346 A˚. The complex [Cu1][ClO4]2, without the piperazine
bridge, shows the metal perfectly in the plane of the nitrogen
atoms.13 Literature reports show a tendency for the reinforced
systems to deviate from square planar coordination to a square
based pyramidal geometry, and this is also found for 7b.9,1025
30
35
40
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50Electrochemistry
The reduction of copper(II) to copper(I) and ligand dissociation is
considered the main pathway for loss of copper frommacrocyclic
BFCs in vivo.2,5 It is therefore undesirable for prospective radio-
pharmaceuticals of copper(II) macrocycles to be reduced at bio-
logically accessible potentials. To assess the reduction of the
novel 15-membered copper(II) macrocycles, cyclic voltammetry of
7a was examined. Experiments were conducted in 0.1 M NaCl
solution, using a glassy carbon working electrode, platinum wire
auxiliary electrode and Ag/AgCl aqueous reference electrode.
Potentials are quoted relative to the saturated calomel electrode
(SCE). The cyclic voltammograms of 7a recorded with scan rates
of 25, 150 and 300 mV s1 are displayed in Fig. 4. The copper(II)–
copper(I) reduction couple for 7awas completely irreversible at all
scan rates tested (5–350 mV s1). With a scan rate of 150 mV s1,
Ep was 0.82 V vs. SCE, which appears to be outside the range of
biologically accessible potentials.14 However displacement of
chloride with a neutral ligand would give a dicationic complex
likely to reduce at more positive potentials. The negative shi of
reduction potential with increased scan rate is consistent with
either an electrochemically irreversible process or reduction fol-
lowed by a rapid chemical reaction. Similar irreversible reduc-
tions occur in the case of [Cu(II)TETA] (Ep ¼ 0.96 V vs. SCE).15
The electrochemical information alone is not suﬃcient to predict
in vivo behaviour of the complexes, but the redox prole suggests
that 7a would not be easily reduced under biological conditions.Fig. 5 (a) Change in the UV/vis spectrum of 7a after addition to human
serum. (b) Percentage decrease in peak absorbance over time for 7a
and [Cu1][Cl]2.
55
Kinetic stability tests by UV-vis spectroscopy
The kinetic stability of 7a was studied under conditions relevant
to biomedical applications.16 The copper(II) complexes of cyclam
1, and the non-macrocyclic ligands 1,4-bis(3-aminopropyl)-
piperazine 4, and 1,2-bis(3-aminopropyl) ethylenediamine 3,This journal is © The Royal Society of Chemistry 2014were also prepared to compare their stability with that of 7a. The
aqueous stability of 7a was rst compared with [Cu1]Cl2, by
monitoring the UV/vis spectra of the complexes over time. In H2O
alone, no changes to either spectrum were observed aer 48 h.
The stability of 7a and [Cu1]Cl2 to a biologically relevant redox
challenge was tested by addition of cysteine to the complexes in
phosphate buﬀer at pH 7.
Aer 20 h incubation in phosphate buﬀer at room temper-
ature, 92% of the initial absorbance at 571 nm remained for 7a.
Aer 20 h incubation aer addition of cysteine, 91% of
compound 7a remained intact.
These results were almost identical to those observed for
[Cu1]Cl2 under the same conditions, which showed 94%
remaining aer 20 h in buﬀer and 93% remaining aer 20 h
with cysteine. Both of these complexes are therefore kinetically
stable under these conditions. The non-macrocyclic complexes
[Cu3][ClO4]2 and [Cu4][ClO4]2 were instantly decolourised on
addition of cysteine, indicating reduction to copper(I), and
ligand loss. Human serum stability tests were then performed.
Solutions of 7a and [Cu1]Cl2 were incubated at 37 C in human
serum, and monitored by UV/vis spectroscopy over 24 h. TheRSC Adv., 2014, xx, 1–7 | 3
45
Fig. 6 GaussView representation of the molecular structure of 7a
cation only (without inclusion of a counter anion) resulting from DFT
optimisation using the protocol uM06/6-31++G(d,p)/SCRF ¼ (cpcm,
solvent ¼ methanol)/temperature ¼ (337.85). The hydrogen atoms
have been omitted for clarity.
Table 2 Signiﬁcant molecular parameters for the DFT optimised
structure of 7a. (The counter anion was excluded for clarity and to
reduce computational time)
Bond Bond length A˚ Bond Angle 
Cu(1)–N(1) 2.070 N(1)–Cu(1)–N(2) 90.70
Cu(1)–N(2) 2.083 N(2)–Cu(1)–N(4) 94.56
Cu(1)–N(3) 2.107 N(4)–Cu(1)–N(3) 71.76
Cu(1)–N(4) 2.107 N(3)–Cu(1)–N(1) 94.62
Cu(1)–Cl(1) 2.434
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20overlaid spectra for 7a at several time points are displayed in
Fig. 5a, and a comparison of 7a with [Cu1]Cl2 is displayed in
Fig. 5b. Aer 3 h in human serum 95% of 7a remained intact
compared with 97% of [Cu1]Cl2 but aer 24 h 77% of 7a
remained intact, compared with 94% for [Cu1]Cl2. Solutions of
compounds [Cu3][ClO4]2 and [Cu4][ClO4]2 became colourless
almost instantly upon addition to human serum, indicating
that the copper was rapidly stripped from the ligand and bound
to the serum proteins (Fig. 6).25
30Thermodynamic stability estimated by DFT calculations in
solution
Thermodynamics of the coordination reactions between
copper(II) chloride dihydrate and ligands 7-benzyl-1,5,7,9,13-
penta-aza-(1,13-ethano)-cyclopentadecane or 1,4,8,11-tetraazacy-
clotetradecane (cyclam) were examined using DFT calculations.Scheme 2 DFT calculated reaction schemes and corresponding
relevant Td parameters at the formation of the 7a cation in solution.
4 | RSC Adv., 2014, xx, 1–7Full coordinates for all stationary points, together with computed
free Gibbs energy and vibrational frequency data, DFT calculated
reaction schemes and corresponding relevant Td parameters at
the formation of the 7a cation in solution are included in
Scheme 2. Both variants likely to form from solution, e.g.with and
without inclusion of a chloride ion in the copper coordination
sphere were modelled, as shown in Scheme 2(a) and (b), respec-
tively. These were found to compare well in terms of Td stability
with the copper(II) cyclam dichloride [Cu1]Cl2 (1c), with 7a being
the most thermodynamically stable in the series (Table 2).35
40
45
50Conclusions
New side-bridged copper(II) complexes of 15-membered pentaa-
zamacrocycles have been prepared in a single-step reaction. The
novel complexes were fully characterised, including an X-ray
crystal structure of the N-allyl derivative. Electrochemical and
aqueous stability studies suggested that these complexes are
reduced outside of a biologically accessible window, and have
good kinetic stability. Their thermodynamic stability, evaluated
by DFT calculations in solution, rendered them potential candi-
dates for kinetic evaluation in biologicalmedia and pointed out to
the fact that these compounds compare well with the established
copper analogues based on the cyclam motif commonly used in
radiochemistry workwith 67Cu and 64Cu. They were found to be of
comparable kinetic stability, albeit marginally less kinetically
stable, than the known 14-membered cyclam analogues in
aqueous environments.5–9 Therefore, these compounds, although
representing useful alternatives to the known systems as synthetic
scaﬀolds for future development work towards BFCs for radio-
pharmaceutical applications, their close similarity to known
systems did not justify in full extensive radiolabelling develop-
ment work with 64Cu(II) at present. Radiolabelling studies are in
progress, encouraged by their thermodynamic and kinetic
stability, particularly with the view to screen their availability to
binding other metals of relevance to PET imaging, such as Ga-68
and evaluate their potential for tagging with targeting biomole-
cules. Those ndings will be reported elsewhere.55Experimental section
General procedure for macrocycle formation
Copper(II) nitrate trihydrate (5 mmol) was added to bis(amino-
propyl)piperazine (1.0 mL, 5.0 mmol) in MeOH (60 mL), andThis journal is © The Royal Society of Chemistry 2014
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1formaldehyde (0.82 mL, 10 mmol) was added. The desired
amine component (5.5 mmol) was added, and the reaction
stirred at reux for 24 h. The reaction was cooled to room
temperature, and analysed by MS.5
10
15
20Copper(II) cyclam dichloride [Cu1]Cl2
Cyclam (0.30 g, 1.5 mmol) was dissolved in EtOH (40 mL)
and [Cu(II)Cl2$2H2O] (0.26 g, 1.5 mmol) was added and
the reaction stirred at reux for 4 h. The reaction was
ltered and ltrate evaporated to dryness. The residue was
recrystallised from nPrOH, yielding purple crystals (0.43 g,
86.6%).25
30
35
40Bis(aminopropyl) ethylene diamine copper(II) diperchlorate
[Cu3][ClO4]2
Bis(aminopropyl)ethylene diamine (0.92 mL, 5.0 mmol), was
dissolved in EtOH (20mL) and a solution of [Cu(II)(ClO4)2$6H2O]
(1.85 g, 5 mmol) in H2O (5 mL) was added. The reaction stirred
for 30min at room temperature, and was chilled in the fridge for
1 h. The purple precipitate was ltered and rinsed with EtOH
(1.95 g, 89.7%). MS (ES+) m/z 236.1074 (calc. for C8H21N4Cu
236.1062) [M  H]+.45
50
55Bis(aminopropyl)piperazine copper(II) diperchlorate [Cu4]
[ClO4]2
Bis(aminopropyl)piperazine (1.03 mL, 5 mmol) was dis-
solved in H2O (15 mL) and [Cu(II)(ClO4)2$6H2O] (1.84 g, 5
mmol) was added. The reaction stirred at room temperature
for 1 h. The solution was stored at room temperature for 4
days, aer which the purple crystals were ltered, and washed
with ice cold H2O. MS m/z 362.09 (calc. for C10H24CuN4ClO4
362.08).This journal is © The Royal Society of Chemistry 20147-Benzyl-1,5,7,9,13-penta-aza-(1,13-ethano)-cyclopentadecane
chloro copper(II) perchlorate (7a)
Bis(aminopropyl)piperazine (1.0 mL, 5.0 mmol) was dissolved
in MeOH (60 mL) and [Cu(II)(NO3)2$3H2O] (1.20 g, 5.0 mmol) was
added. Formaldehyde (37% in H2O), (1.66 mL, 20 mmol) and
benzylamine (0.60 mL, 5.5 mmol) were added. The reaction
stirred at reux for 24 h. The reaction was cooled, ltered, and the
ltrate evaporated to dryness under reduced pressure. The
residue was dissolved inH2O (5mL) and loaded onto a Sephadex-
SP C25 column (35  200 mm), washed with H2O (50 mL) and
eluted with NaCl (aq., 0.1 M). The major band was concentrated
under reduced pressure. MeOH (20 mL) was added, and the
mixture was ltered. Saturated NaClO4 (aq.) was added to the
ltrate, and the solution was stored at 4 C for 7 days. Fine blue
crystals were formed, which were ltered and rinsed with ice-cold
H2O (2 mL) (1.79 g, 67.7%). Elemental analysis (calc. + 2H2O) C
40.88 (40.32), H 6.45 (6.59), N 12.42 (12.37). UV/vis lmax (H2O) 571
nm (3 ¼ 259.7 mol1 dm3 cm1). IR n (cm1) 3424, 3205, 2870,
1471, 1416, 1287, 1221, 1097, 1026, 968, 925, 842, 788, 746, 701,
622. MS (ES+) m/z 429.1737 (calc. for C19H33N5ClCu 429.1720).7-Allyl-1,5,7,9,13-penta-aza-(1,13-ethano)-cyclopentadecane
chloro copper(II) perchlorate (7b)
[Cu(II)(NO3)2$3H2O] (0.60 g, 2.5 mmol) was dissolved in
MeOH (40 mL) and bis(3-aminopropyl)piperazine (0.50 mL, 2.5
mmol) was added. Formaldehyde (37% in H2O, 0.83 mL, 10
mmol) and allylamine (0.23 mL, 2.75 mmol) were added. The
mixture was reuxed for 24 h. The reaction mixture was evap-
orated to dryness, and product redissolved in H2O, and loaded
onto a Sephadex-SP C25 column (35  200 mm). Elution with
NaCl (aq., 0.1 M) yielded 3 bands, and the product was found in
the major band, which was the rst eluted. The solution was
evaporated, MeOH was added and the mixture was ltered.
Excess saturated NaClO4 (aq.) was added, and the mixture
cooled to 4 C for 7 days, aer which blue needles formed. The
product was ltered, rinsed with ice-cold H2O (2 mL) and dried
in air (0.71 g, 59.2%). Elemental analysis (calc.) C 37.58 (37.54),
H 6.47 (6.51), N 14.46 (14.59). UV/vis lmax (H2O) 571 nm (3 ¼
269.7 mol1 dm3 cm1). IR n (cm1) 3442, 3194, 2870, 2360,
1470, 1419, 1293, 1093, 1027, 968, 922, 787, 623. MS (ES+) m/z
343.1801 (calc. for C15H30N5Cu 343.1797) [M  H]+.RSC Adv., 2014, xx, 1–7 | 5
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1
5Kinetic stability tests
The copper macrocycles were prepared as 0.015 M stock solu-
tions in DMSO. Dilutions were performed as described below.
Solutions were prepared in quartz cuvettes (3 mL) for direct
monitoring by UV/vis at desired time-points. The cuvettes were
removed from the instrument between recordings.10Phosphate buﬀer stability
The stock solution (0.1 mL) was added to phosphate buﬀer (pH
¼ 7.0, 2.9 mL), and stored at room temperature between
recordings.15
Cysteine challenge
The stock solution (0.1 mL) was added to phosphate buﬀer (pH
¼ 7.0, 1.9 mL), and cysteine solution (1.0 mL, 2 mM in phos-
phate buﬀer), (10–20 equivalents of cysteine). The solutions
were stored at room temperature.20
25Human serum binding
The stock solution was prepared at 0.015 M in H2O. The stock
(0.2 mL) was added to human serum (from human male AB
plasma, Sigma-Aldrich) (2.8 mL) and incubated in a water bath
at 37 C between recordings.30
35
40
45Synchrotron X-ray diﬀraction studies
Blue-coloured, single crystals were grown by the slow diﬀusion
of diethyl ether vapor into an acetonitrile solution (ca. 1 mg
mL1) of 7b. A single crystal of 7b was selected under inert
atmosphere, encased in peruoro-polyether oil, and mounted
on the end of a glass ber. The ber, secured on a goniometer
head was then placed under a stream of cold nitrogen main-
tained at 150 K.
Crystals were small and weakly diﬀracting, so a synchrotron
radiation source was used to collect diﬀraction data for this
compound (at 150 K). Data were collected at Station 9.8,
Daresbury SRS, UK, using a Bruker SMART CCD diﬀractometer.
The structure was solved by direct methods using the program
SIR92.17 The renement and graphical calculations were per-
formed using the CRYSTALS18 soware package. The structure
was rened by full-matrix least-squares procedure on F. All non-
hydrogen atoms were rened with anisotropic displacement
parameters. Hydrogen atoms were located in Fourier maps and
their positions adjusted geometrically (aer each cycle of
renement) with isotropic thermal parameters.50
55Selected crystallographic data
Moiety formula [C15 H31 Cl Cu N5]
+, [ClO4]
 M ¼ 477.88, Z ¼ 8,
monoclinic, space group P21/n, a ¼ 11.9964(8) A˚; b ¼
15.8250(11) A˚, c ¼ 21.4986(15) A˚; beta ¼ 91.7800(10), U ¼
4079.4(5) A˚3, T ¼ 150(2) K, m ¼ 1.364 mm1. Of 38 420 reec-
tions measured, 11 021 were independent (Rint ¼ 0.061); nal R
¼ 0.0437 (4626 reections with I > 3s(I) and wR¼ 0.0497). Fig. 3
contains the ORTEP diagram (40% probability) and Table 1 lists
signicant molecular parameters.6 | RSC Adv., 2014, xx, 1–7DFT computational details
Full coordinates for all stationary points, together with computed
free Gibbs energy and vibrational frequency data, are also avail-
able via the corresponding Gaussian 09 output les, stored in the
digital repository (DOI: 10.6084/m9.gshare.907517). All calcu-
lations employed the following protocol: uM06/6-31++G(d,p)/
SCRF ¼ (cpcm, solvent ¼ methanol)/temperature ¼ (337.85).
The M06 functional is one of the hybrid meta-generalized
gradient-approximations functionals (hybrid meta-GGAs), devel-
oped by the group of Prof. Donald Truhlar at the University of
Minnesota. M06 includes 27% of Hartree–Fock exchange, has
been parametrised including both transition metals and non-
metals, and is recommended for application in transition metal
thermochemistry and non-covalent interactions.19 The calcula-
tions were all carried out using a temperature of 337.85 K and the
self-consistent-reaction-cavity continuum solvation model to
account for the coordination reactions conditions (methanol
reux). Implementation of the self-consistent-reaction-cavity
continuum solvation model has recently been enhanced to
allow eﬃcient evaluation of rst and second energy derivatives,
following an earlier suggestion of the method.20,21 All open shell
systems were treated with the unrestricted approach. The split-
valence double z with polarization and diﬀuse functions
6-31++G(d,p) basis set was selected to account for potential ions
and nonbonding interactions, while allowing the models to scale
up to the maximum size of 59 atoms, and an associated
maximum of 677 basis functions.
All geometries were fully optimized without any symmetry or
geometry constrains. The nature of all the stationary points as
minima was veried by calculations of the vibrational frequency
spectrum, and characterised by no imaginary mode. Free
energies were calculated within the harmonic approximation
for vibrational frequencies. Only the most stable conforma-
tional isomers are reported for all intermediates. All calcula-
tions were performed using the Gaussian09 suite of codes.22Acknowledgements
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